Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

PURPOSE: To improve the delivery of liposomes to tumors using P-selectin glycoprotein ligand 1 (PSGL1) mediated binding to selectin molecules, which are upregulated on tumorassociated endothelium. METHODS: PSGL1 was orientated and presented on the surface of liposomes to achieve optimal selectin binding using a novel streptavidin-protein G linker molecule. Loading of PSGL1 liposomes with luciferin allowed their binding to e-selectin and activated HUVEC to be quantified in vitro and their stability, pharmacokinetics and tumor accumulation to be tested in vivo using murine models. RESULTS: PSGL1 liposomes showed 5-fold (p 7-fold (p 3-fold enhancement in the level of delivery to tumors (p 

Original publication

DOI

10.1007/s11095-012-0875-5

Type

Journal article

Journal

Pharm Res

Publication Date

02/2013

Volume

30

Pages

352 - 361

Keywords

Animals, Benzothiazoles, Drug Delivery Systems, Human Umbilical Vein Endothelial Cells, Humans, Liposomes, Membrane Glycoproteins, Mice, Neoplasms, P-Selectin, Surface Properties